Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Bio-Thera Sells US Rights to Autoimmune Biosimilar in $150 Million Deal

publication date: Aug 27, 2021

Guangzhou Bio-Thera Solutions out-licensed US commercialization rights for its Stelara® (ustekinumab) biosimilar to Hikma Pharma in a $150 million agreement. Jansen’s Stelara® inhibits inflammation in autoimmune disorders including Crohn's disease and ulcerative colitis. One month ago, Bio-Thera started US-EU Phase III clinical trial of BAT2206 in psoriatic (PsO) patients, Bio-Thera will receive $20 million upfront and up to $130 million in milestones. Hikma also has a first-right-to-negotiate for European rights to the biosimilar. More details....

Stock Symbols: (SHA: 688177) (LSE: HIK)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.